Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $20.00 at HC Wainwright

Key Points

• HC Wainwright raised its price target for Astria Therapeutics (NASDAQ:ATXS) from $16.00 to $20.00, indicating a potential upside of 157.86% from its previous close.
• Other analysts, including JMP Securities and Cantor Fitzgerald, have positive ratings on the stock, with price targets ranging from $26.00 to $49.00, contributing to a consensus price target of $30.20.
• Astria Therapeutics recently reported an earnings per share (EPS) of ($0.57), which beat estimates, and has a current market cap of approximately $437.75 million.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) had its target price increased by HC Wainwright from $16.00 to $20.00 in a research note issued on Wednesday, Marketbeat Ratings reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 183.69% from the company's previous close.

ATXS has been the subject of several other reports. JMP Securities upped their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $49.00 target price on shares of Astria Therapeutics in a research note on Wednesday. Finally, Citigroup restated an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $30.20.

Astria Therapeutics Trading Down 5.7%

Shares of Astria Therapeutics stock traded down $0.43 on Wednesday, hitting $7.05. 1,303,719 shares of the company traded hands, compared to its average volume of 348,468. The company has a market cap of $397.90 million, a P/E ratio of -3.51 and a beta of 0.42. The firm's 50-day simple moving average is $6.77 and its 200 day simple moving average is $5.76. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. Analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATXS. JPMorgan Chase & Co. grew its position in shares of Astria Therapeutics by 4,607.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock worth $9,091,000 after buying an additional 1,660,039 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after purchasing an additional 550,706 shares during the period. Nantahala Capital Management LLC raised its position in Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock worth $5,733,000 after acquiring an additional 400,000 shares during the period. Vestal Point Capital LP raised its position in Astria Therapeutics by 8.2% during the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock worth $24,238,000 after acquiring an additional 342,000 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Astria Therapeutics in the second quarter valued at about $1,608,000. Institutional investors own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.